ARTICLE | Clinical News
Blueprint reports early data for RET inhibitor
April 16, 2018 8:08 PM UTC
Blueprint Medicines Corp. (NASDAQ:BPMC) reported data from the Phase I ARROW trial of BLU-667 to treat ret proto-oncogene (RET)-altered solid tumors. BLU-667 is a RET inhibitor.
Among 14 evaluable patients with RET-altered non-small cell lung cancer (NSCLC), once-daily BLU-667 led to an overall response rate (ORR) of 50%, including five confirmed partial responses (PRs) and two unconfirmed PRs...
BCIQ Target Profiles